Weekly Digital Marketing / SEO Briefing — Cosentyx

Week ending August 23, 2026

1. Content opportunities this week

1. “For Cosentyx dosing in plaque psoriasis, what loading regimen and maintenance dose should I follow?”
   AI answers are very short (68–129 words) and materially inconsistent on whether loading occurs for four or five weeks and when maintenance begins. This is a high-value opportunity for a clear, label-aligned dosing page, schedule graphic, and FAQ.

2. “How do you administer Cosentyx (prefilled pen vs syringe vs infusion), and what are the steps around taking it out of the fridge and injecting?”
   Responses are longer but largely generic and repeatedly defer to the Instructions for Use. A device-specific administration hub could provide clearer, citable guidance on storage, room-temperature handling, injection steps, and when professional administration applies.

3. “Can Cosentyx be used during pregnancy or breastfeeding, and what guidance does the label give about live vaccines for infants exposed in utero or via lactation?”
   All seven answers discuss pregnancy/lactation, while the category increased from 15 to 19 this week. The topic also contains inconsistent treatment of contraindication language and infant vaccine guidance, supporting a definitive label-based explainer.

4. “What monitoring is recommended while on Cosentyx, and what lab tests or screening (like tuberculosis) are required before starting?”
   This recurring question generates heavily hedged answers and inconsistent coverage of TB, hepatitis, IBD symptoms, allergic reactions, and ongoing monitoring. Build a structured “before and during treatment” checklist.

5. “What IL-17 role does Cosentyx target, and how is that commonly described compared with other psoriasis medicines?”
   Answers are exceptionally thin (97–124 words). A plain-language mechanism page comparing IL-17A, TNF, IL-12/23, and IL-23 pathways could become a strong explanatory source.

2. Where competitors may be winning visibility

Competitor mentions rose sharply this week: Humira 18, Enbrel 17, Stelara 16, and Taltz 16. The clearest visibility gaps are:

• Humira: appears throughout the plaque psoriasis comparison question, “How does Cosentyx compare with Humira…[on] effectiveness or side effects?” All seven responses mention Humira.
• Enbrel: appears in all seven answers to “Is Cosentyx ‘stronger’ than Enbrel?”
• Taltz: appears in all seven answers to the nurse-facing Cosentyx-versus-Taltz question and in several mechanism/switching answers.
• Stelara: appears in all seven answers to “I’m being offered Cosentyx instead of Stelara…what are the practical differences?”

Prioritize comparison pages that answer the full practical question—not just mechanism—including dosing, indications, response expectations, safety considerations, and access caveats.

3. Topics worth resolving with authoritative content

• Plaque psoriasis dosing: resolve the four-versus-five-week loading and maintenance-timing discrepancies with the current applicable label.
• Pregnancy, lactation, and infant live vaccines: clearly separate “contraindication,” “not recommended,” and “use only if benefit outweighs risk,” and state the label’s infant vaccination guidance.
• Major safety warnings: answer “What boxed warnings or major safety warnings apply to Cosentyx?” with an explicit distinction between no boxed warning and Warnings and Precautions, including infection, TB, IBD, and hypersensitivity.

4. Prioritization — recurring vs. one-off

Recurring investment: infection/TB, IBD, hedging, competitor comparisons, dosing, pregnancy/lactation, and administration have appeared repeatedly across the rolling history. Infection rose to 87 and IBD to 40 this week; hedging reached 120.

Monitor, but do not overcommit: off-label questions remain low-volume (3 mentions), while kidney/liver impairment is recurring but small (6). Biosimilar/generic questions are recurring and growing modestly (11), warranting an FAQ rather than a major hub this week.

5. Recommended content actions (ranked)

1. Publish a label-aligned plaque psoriasis dosing guide addressing the exact dosing question and conflicting AI schedules.
2. Publish an administration and storage hub covering pen, syringe, infusion, refrigeration, and injection steps.
3. Create a pregnancy/breastfeeding and infant-vaccine explainer with precise label terminology.
4. Build a Cosentyx vs Humira/Taltz/Stelara comparison cluster, starting with plaque psoriasis and practical differences.
5. Update safety content with a TB, infection, IBD, monitoring, and warnings checklist.